Therion raises $30 million in fourth round.
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Therion Biologics
|
$30M
|
Hans-Werner Hector |
The funds will go to the clinical development of PanVac-VF and ProstVaC-VF, its lead product candidates to treat pancreatic cancer and prostate cancer. |
|
ProMetic Life Sciences
|
$15M
|
Sprott Securities |
ProMetic has been developing treatments for cancer and inflammation/autoimmune diseases. |
|
Exagen Diagnostics
|
$7M
|
Tullis-Dickerson & Co |
Exagen is developing genomic market IVD kits for breast cancer. |
|
AmpliMed Corp
|
$5M
|
Biotech Insight Ventures |
The money will go to expand its pipeline of cancer drugs and push new clinical trials. |
|
TriMed Research
|
$5M
|
Inventages venture capital investments |
TriMed is beginning to develop therapies based on research related to the mammary gland protein designated as MAA. |